(S (NP (NP (NNP De)) (PP (FW novo) (NP (JJ therapeutic) (NN design)))) (VP (VBZ is) (VP (VBN challenged) (PP (IN by) (NP (NP (DT a) (JJ vast) (NN chemical) (NN repertoire)) (CC and) (NP (NP (JJ multiple) (NNS constraints)) (PP (JJ such) (IN as) (NP (NP (JJ high) (NML (JJ broad) (HYPH -) (NN spectrum)) (NN potency)) (CC and) (NP (JJ low) (NN toxicity))))))))) (. .))
(S (NP (PRP We)) (VP (VBP propose) (NP (NP (NP (NN CLaSS)) (-LRB- -LRB-) (VP (VBN Controlled) (NP (NP (NP (JJ Latent) (NN attribute) (NN Space) (NN Sampling) (-RRB- -RRB-)) (HYPH -) (NP (DT a) (NN novel))) (CC and) (NP (NP (ADJP (NP (NP (JJ efficient) (JJ computational) (NN method)) (PP (IN for) (NP (NN attribute)))) (HYPH -) (VBN controlled)) (NN generation)) (PP (IN of) (NP (NNS molecules))))))) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBZ leverages) (NP (NN guidance)) (PP (IN from) (NP (NP (NNS classifiers)) (VP (VBN trained) (PP (IN on) (NP (NP (DT an) (JJ informative) (NN latent) (NN space)) (PP (IN of) (NP (NP (NNS molecules)) (VP (VBN modeled) (S (VP (VBG using) (NP (DT a) (JJ deep) (NN generative) (NN autoencoder))))))))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB further)) (VP (VBP screen) (NP (DT the) (ADJP (VBN generated)) (NNS molecules)) (PP (IN by) (S (VP (VBG using) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NML (JJ deep) (NN learning)) (NNS classifiers)))) (PP (IN in) (NP (NN conjunction))) (PP (IN with) (NP (NP (JJ novel) (JJ physicochemical) (NNS features)) (VP (VBN derived) (PP (IN from) (NP (NML (JJ high) (HYPH -) (NN throughput)) (JJ molecular) (NNS simulations)))))))))) (. .))
(S (NP (DT The) (VBN proposed) (NN approach)) (VP (VBZ is) (VP (VBN employed) (PP (IN for) (S (VP (VBG designing) (NP (NP (JJ non-toxic) (JJ antimicrobial) (NNS peptides)) (-LRB- -LRB-) (NP (NNS AMPs)) (-RRB- -RRB-)) (PP (IN with) (NP (NP (JJ strong) (NML (JJ broad) (HYPH -) (NN spectrum)) (NN potency)) (, ,) (SBAR (WHNP (WDT which)) (S (VP (VBP are) (VP (VBG emerging) (NP (NN drug) (NNS candidates)) (PP (IN for) (S (VP (VBG tackling) (NP (JJ antibiotic) (NN resistance)))))))))))))))) (. .))
(S (NP (NP (NML (NML (NN Synthesis)) (CC and) (NML (JJ wet) (NN lab))) (NN testing)) (PP (IN of) (NP (QP (RB only) (CD twenty)) (VBN designed) (NNS sequences)))) (VP (VBD identified) (NP (CD two) (ADJP (JJ novel) (CC and) (JJ minimalist)) (NNS AMPs)) (PP (IN with) (NP (NP (JJ high) (NN potency)) (PP (IN against) (NP (ADJP (UCP (ADJP (NP (JJ diverse) (NN Gram)) (HYPH -) (JJ positive)) (CC and) (NML (NNP Gram))) (HYPH -) (JJ negative)) (NNS pathogens))))) (, ,) (PP (VBG including) (NP (NP (DT the) (ADJP (JJ hard) (HYPH -) (S (VP (TO to) (HYPH -) (VP (VB treat) (NP (ADJP (JJ multidrug) (HYPH -) (JJ resistant)) (NNP K.)))))) (NNS pneumoniae)) (, ,) (CONJP (RB as) (RB well) (IN as)) (NP (JJ low) (ADJP (ADJP (FW in) (FW vitro)) (CC and) (ADJP (FW in) (FW vivo))) (NN toxicity))))) (. .))
(S (NP (DT The) (VBN proposed) (NN approach)) (ADVP (RB thus)) (VP (VBZ presents) (NP (NP (DT a) (JJ viable) (NN path)) (PP (IN for) (NP (NP (ADVP (RBR faster)) (NN discovery)) (PP (IN of) (NP (ADJP (JJ potent) (CC and) (JJ selective)) (NML (JJ broad) (HYPH -) (NN spectrum)) (NNS antimicrobials)))))) (PP (IN with) (NP (NP (DT a) (JJR higher) (NN success) (NN rate)) (PP (IN than) (NP (NML (NML (NN state)) (HYPH -) (PP (IN of) (HYPH -) (NP (DT the) (HYPH -) (NN art)))) (NNS methods)))))) (. .))
